Data From Multiple Ongoing Trials Of Vir Biotech's HBV Therapies Show Promising Action

  • Vir Biotechnology Inc VIR announced new data from its hepatitis B virus (HBV) portfolio aimed at achieving a functional cure.
  • New preliminary data from an ongoing Phase 2 trial demonstrated that 30.8% of participants receiving 48 weeks of VIR-2218 combined with pegylated interferon alpha (PEG-IFN-α) achieved HBsAg seroclearance with anti-HBs seroconversion. 
  • Additionally, 48 weeks of VIR-2218 plus PEG-IFN-α provided greater reductions in hepatitis B surface antigen (HBsAg) compared to VIR-2218 alone or with shorter regimens of the combination. 
  • No new safety signals were identified.
  • Related: This Hepatitis Stock Has 'Multiple Paths To Value Creation,' Expects To Double, Bullish Analyst Predicts.
  • New results from Part A of the Phase 2 MARCH trial demonstrated a mean HBsAg reduction of >2.5 log10 IU/mL. 
  • The combination of VIR-2218 and VIR-3434 through up to 20 weeks of treatment in Part A was generally well tolerated. 
  • The company is evaluating the combination of VIR-2218, VIR-3434, and PEG-IFN-α in Part B of the MARCH trial. Initial data from Part B are expected in the second half of 2023.
  • Additionally, Phase 1 data demonstrated that a single 75 mg or 300 mg dose of VIR-3434 resulted in rapid reductions in HBsAg and HBV DNA in chronic HBV infection without nucleot(s)ide transcriptase inhibitor (NRTI) therapy. 
  • Price Action: VIR shares are down 2.96% at $24.90 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!